Transcription factor involved in the induction of oxygen regulated genes. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation seems to require recruitment of transcriptional coactivators such as CREBPB and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD. Efficient DNA binding requires dimerization with another bHLH protein. Heterodimerizes with ARNT. Interacts with CREBBP. Interacts with EGLN1. Interacts with VHL. Expressed in most tissues, with highest levels in placenta, lung and heart. Selectively expressed in endothelial cells. Note: This description may include information from UniProtKB.
Protein type: DNA binding protein; Transcription factor
Molecular Function: histone acetyltransferase binding; signal transducer activity; protein binding; DNA binding; protein heterodimerization activity; sequence-specific DNA binding; transcription factor binding
Biological Process: transcription from RNA polymerase II promoter; mitochondrion organization and biogenesis; myoblast cell fate commitment; embryonic placenta development; regulation of heart rate; somatic stem cell maintenance; cell maturation; norepinephrine metabolic process; signal transduction; iron ion homeostasis; visual perception; response to hypoxia; erythrocyte differentiation; positive regulation of transcription from RNA polymerase II promoter; blood vessel remodeling; angiogenesis; regulation of transcription from RNA polymerase II promoter in response to oxidative stress; surfactant homeostasis; lung development
Alt. Names/Synonyms: Basic-helix-loop-helix-PAS protein MOP2; BHLHE73; Class E basic helix-loop-helix protein 73; ECYT4; endothelial PAS domain protein 1; Endothelial PAS domain-containing protein 1; EPAS-1; EPAS1; HIF-1-alpha-like factor; HIF-1alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; hypoxia-inducible factor 2 alpha; Hypoxia-inducible factor 2-alpha; Member of PAS protein 2; MOP2; PAS domain-containing protein 2; PASD2
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.